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Motor neuron dysfunction due to spinal cord
injury after a successful operation on the thoracic aorta
is a disastrous complication in humans. The reported
incidences of paraplegia range from 0.9% to 40%1,2 in
operations on the thoracic aorta. The cause of acute
spinal cord dysfunction is believed to be due to its
ischemic damage during cross-clamping. Ischemia can
occur because of permanent exclusion of the essential
intercostal arterial blood supply to the spinal cord or
from temporary interruption of blood flow to the
spinal cord.3 However, patients undergoing thoracic
aneurysm repair who awake with no neurologic deficit
immediately after the operation may sometimes even-
tually develop paraplegia.4 In an attempt to prevent
this complication, various methods of spinal cord pro-
tection have been suggested, including temporary
shunts, partial bypass, and hypothermia. Regardless of
the surgical technique or method of spinal cord pro-
tection used, no method has been developed that
totally prevents the development of paraplegia.5
Many recent studies on ischemic cerebrovascular
diseases revealed that there are two major ways of neu-
ronal cell death, necrosis and apoptosis.6 Necrosis usu-
ally occurs after acute ischemia as a result of reduction
of tissue adenosine triphosphate level accompanied by
edema formation and concomitant death of glial and
vascular cells. In contrast, neuronal apoptosis occurs
days after ischemia without a reduction in adenosine
triphosphate level or edema formation and concomi-
tant death of glial and vascular cells. Our previous
study reported that the induction of Fas antigen in
ischemic spinal motor neurons was related to the
apoptosis and they eventually die.7 In any event, some
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putative protective proteins such as neurotrophic fac-
tors and heat shock protein may prevent these neu-
ronal deaths if the proteins could effectively work
under an emergency condition such as ischemia.8-10
However, the expression of the genes from their own
genome is greatly limited in ischemic neurons.
Furthermore, such proteins are greatly limited to work
in ischemic neurons as pharmaceutical agents because
it is difficult for them to directly enter the spinal cord
as a result of the nature and size of the molecules (pro-
tein/peptide).6
Recent studies have suggested that the use of
replication-defective adenoviral vectors has provided
a novel strategy for direct gene transfer into the cen-
tral nervous system.11,12 An adenoviral vector can
transduce a given gene into nonproliferating cells
such as neuronal cells.13 However, the transfer and
expression of adenoviral-mediated gene have not
been reported in ischemic spinal cord. For a possible
future application of gene therapy for ischemic para-
plegic patients, the present study was designed to
examine whether spinal cord motor neuron cells
could effectively produce an exogenously transferred
gene during and after ischemia.
MATERIAL AND METHODS
Animal models. Twenty-four Japanese domes-
ticated white rabbits weighing 2 to 3 kg were used
in this study and divided into two subgroups, the
sham control group and the 15-minute ischemia
group. Anesthesia was induced with intramuscular
administration of ketamine at a dose of 50 mg/kg
and maintained with 2% halothane inhalation. A 5F
thermodilution catheter (405; B Braun Melsungen
AG) was inserted through a femoral artery and
advanced 15 cm forward into the abdominal aorta.
Preliminary investigations confirmed that the bal-
loon in the distal end of the thermodilution catheter
was positioned 0.5 to 1.5 cm just distal to the left
renal artery. During the experiment, aortic pressures
were continuously monitored at both the proximal
and distal positions of the distal balloon. Body tem-
perature was monitored with a rectal thermistor and
was maintained at 37°C with the aid of a heating pad
during surgery and subsequent ischemia. Animals
were allowed to recover at ambient temperature and
were killed with deep anesthesia of sodium pento-
barbital (100 mg/kg intravenously) at 1, 2, 4, and 7
days after reperfusion (n = 3 at each time point). In
the sham control group, animals were killed at 1, 2,
4, and 7 days after insertion of the catheter into
abdominal aorta without inflation of the balloon.
Spinal cords were quickly removed immediately after
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death, using the plunger of a 1-mL syringe.14 The
tissue samples for immunohistochemistry were
frozen in powdered dry ice and stored at –80°C. In
the experiment, rabbits were treated in accordance
with the Declaration of Helsinki and the “Guiding
Principles in the Care and Use of Animals.” Also,
the experimental and animal care protocol was
approved by the Animal Care Committee of the
Tohoku University School of Medicine.
Neurologic assessment. To evaluate the effect
of LacZ versus vehicle, neurologic function was
observed at 2 and at 7 days after the procedure. To
determine the ischemic changes, another series of 15
animals that were injected with vehicle (5 m L of
vehicle consisting of 10 mmol/L Tris-HCl, pH 7.4,
1 mmol/L MgCl2, and 10% glycerol) were allowed
to recover for 2 and 7 days after 15-minute ischemia
(n = 5, respectively) and 7 days after sham operation
(n = 5). Animals were classified into a five-point scale
according to the method of Johnson et al15: 0, hind-
limb paralysis; 1, severe paraparesis; 2, functional
movement, no hop; 3, ataxia, disconjugate hop; 4,
minimal ataxia; 5, normal function. Two individuals
without knowledge of the treatment independently
graded neurologic function. Statistical analyses of
the neurologic scores were done with the Mann-
Whitney U test.
Adenoviral vector constructs. The recombi-
nant adenoviral vector used in this study was based
on type 5 adenovirus, essentially the same as in pre-
vious reports.12,16 In brief, the E3 region of the ade-
novirus genome was deleted, and a cassette contain-
ing E coli lacZ gene (encoding b -galactosidase) dri-
ven by cytomegalovirus promoter, the nuclear
localizing signal of simian virus 40 (SV40) large T
antigen and SV40 polyadenylation signal were insert-
ed into the E1 region of the adenovirus genome by
homologous recombination. With this promoter,
lacZ gene of the episomally located adenovirus vec-
tor may be transcribed as mRNA in the nucleus, the
mRNA translated into the protein in the cytoplasm,
and then the product protein transported again into
the nucleus. The adenoviral vector, designated as
AdCMVnLacZ, was propagated in the 293 cells
(CRL1573; American Type Collection) and purified
and titered as previously described.17
In vivo gene transfer. Immediately after spinal
cord ischemia, the adenoviral vector was inoculated.
With immobilization using stereotactic apparatus,
AdCMVnLacZ (2.5 · 109 plaque forming units in 5
m L of vector vehicle consisting of 10 mmol/L Tris-
HCl, pH 7.4, 1 mmol/L MgCl2, and 10% glycerol)
was administered to the dorsal white matter via the
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intervertebral disc L3 in a depth of 20 mm from the
surface of the skin using a 10-m L sterile Hamilton
syringe (Gastight Highperformance Syringe;
Hamilton, Reno, Nev) and a 26-gauge needle (0.47
mm in outer diameter). Preliminary investigations
confirmed that the end of the needle was positioned
1 to 3 mm just dorsal to the central canal of the
spinal cords. The injections (5 m L) were slowly com-
pleted over 10 minutes. During the injection, the
needle was pulled gradually at a rate of 3.5 mm/10
min and finally removed at 10 minutes.
Evaluation of gene transfer and expression.
The samples were cut transversely at about the L2 or
L3 level on a cryostat at –18°C with 15-m m thickness
and collected on poly-L-lysine-coated slides (MUTO
Pure Chemicals, Tokyo, Japan). The sections were
initially fixed with an ice-cold solution of 2%
formaldehyde + 0.2% glutaraldehyde in phosphate-
buffered saline (PBS, pH 7.4) for 5 minutes. After
three washes with cold PBS, the sections were incu-
bated for 6 hours at 30°C in the staining solution
consisting of 5 mmol/L K4Fe(CN)6, 5 mmol/L
K3Fe(CN)6 (Wako Chemicals, Tokyo, Japan), and 2
mmol/L MgCl2 in PBS containing 50 m g/mL X-Gal
(5-bromo-4-chloro-3-indolyl-b -D-galactopyranoside;
Boehringer-Mannheim, Mannheim, Germany). X-
Gal was initially dissolved in N, N-dimethylfor-
mamide (Wako Chemicals) at 10 mg/mL and diluted
in the above staining solution (1/200) before the
reaction.
After the reaction of X-Gal, the sections were
dipped for 1 second in hematoxylin and then for 20
seconds in eosin (light hematoxylin-eosin staining) as
a counterstaining. With the counterstaining, the spinal
cord sections were examined by light microscopy and
the number of lacZ positive motor neurons was count-
ed in five sections per animal.
Immunocytochemistry. Immediately after the
reaction of X-Gal, a set of spinal cord sections were
subsequently stained with an antibody for Fas anti-
gen by an immunohistochemical technique accord-
ing to our previous reports.7 In brief, after the reac-
tion for b -gal activity at 30°C for 6 hours, the sec-
tions were rinsed in 0.1 mol/L PBS for 20 minutes
and blocked in 2% normal horse serum for 2 hours at
room temperature. Then they were incubated with a
monoclonal mouse anti-Fas antibody (F22120;
Transduction Laboratories, Lexington, Ky) in PBS
containing 2% normal horse serum and 0.2% Triton
X-100 for 20 hours at 4°C. After quenching endoge-
nous peroxidase activity by exposing slides to 0.3%
H2O2 and 10% methanol for 20 minutes, the slides
were washed in PBS and incubated for 3 hours with
biotinylated anti-mouse immunoglobulin G (PK-
6102; Vector Laboratories, Burlingame, Calif) at
1:200 dilution in PBS containing 0.018% normal
horse serum. Subsequently they were incubated with
avidin-biotin–horseradish peroxidase complex (PK-
6102; Vector Laboratories, Burlingame, Calif). The
slices were colorized with DAB/H2O2 solution. To
ascertain specific binding of antibody for the protein,
a set of sections were stained in a similar way without
the first antibody and the number of Fas + lacZ 
positive motor neurons were counted in five sections
per animal.
RESULTS
Neurologic outcome. The results are summa-
rized in Table I. In the sham operation + vehicle
group (n = 5) after the procedure, all rabbits were
normal at 2 and 7 days after the procedure (grade
5). In the 15-minute ischemia + vehicle group at 2
days after the procedure (n = 5), 2 rabbits (40%)
were normal (grade 5), 2 rabbits (40%) had minimal
ataxia (grade 4), and 1 rabbit (20%) had ataxia
(grade 3). In the 15-minute ischemia + vehicle
group at 7 days after the procedure (n = 5), 3 rab-
bits (60%) did not hop (grade 2), and 2 rabbits
Table I. Neurologic score at 2 days and 7 days after procedure
15-min ischemia + vehicle 15-min ischemia + lacZ
Animal Sham control 2 d 7 d 2 d 7 d
1 5 5 3 5 3
2 5 5 3 5 3
3 5 5 4 3 2
4 5 4 2
5 5 3 2
Mean ± SD 54 ± 0* 4.44 ± 0.89** 2.8 ± 0.84 4.34 ± 1.16 2.7 ± 0.58
*P = .009 compared with 7 days after procedure in 15-minute ischemia group.
**P = .021 compared with 7 days after procedure in 15-minute ischemia group.
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(40%) had ataxia (grade 3). There was a significant
difference between the Johnson’s neurologic scores
at 2 days and at 7 days after the procedure in the 15-
minute ischemia group (P = .021).
In the 15-minute ischemia + lacZ group at 2 days
after the procedure (n = 3), 2 rabbits (67%) were nor-
mal (grade 5), and 1 rabbit (33%) had ataxia (grade
3). In the 15-minute ischemia + lacZ group at 7 days
after the procedure (n = 3), 2 rabbits (67%) had atax-
ia (grade 3), and 1 rabbit (33%) did not hop (grade
2). There was no difference between the Johnson’s
neurologic scores at 2 days and at 7 days after the
Fig 1. Representative microphotographs of sham control (a-e) and 15-minute ischemic spinal
cord (f-h) showing expression of the lacZ gene as blue color. a is at 1 day, b is at 2 days, c is at 4
days, and d is at 7 days after injection of adenoviral vectors. e shows the route of the injection
needle. f is at 2 days, g is at 4 days, and h is at 7 days of reperfusion. Note the predominant
expression of the lacZ gene in the motor neuronal nucleus (a and f, arrowheads). (Bar = 100 m m.)
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procedure in the 15-minute ischemia group with or
without lacZ gene (P = .870). Thus, 15 minutes of
ischemia did affect neuronal function, and direct
injection of vehicle or lacZ gene into dorsal white
matter did not affect neuronal function.
Traumatic changes. Histologic examination
with light hematoxylin-eosin and X-Gal staining
showed a minimum necrotic change in the portion
of needle entry at the surface of the dorsal white
matter of the spinal cord. No bleeding was found
through the needle route in control and ischemic
spinal cords. Cellular loss or reactive astrogliosis was
not observed around the needle and blue stained
cells that were positive for lacZ in the dorsal white
matter (Fig 1, e).
Transfer and expression of the lacZ gene. A
summary of the lacZ gene expression is shown in
Table II and Figs 1 and 2. In the sham control
spinal cord, adenoviral vector was transferred, and
the lacZ gene was already expressed at 1 day in
some astrocytes in dorsal white matter and anterior
motor neurons (Fig 1, a) (3.2 ± 2.4/ventral horn;
mean ± SD) in ventral horn. The number and stain-
ing gradually increased at 2 days with their peaks on
the same days (Fig 1, b) (16.8 ± 3.5/ventral horn).
At 4 and 7 days after the injection, the gene expres-
sion in motor neurons continued at the levels of 2
days after injection (Fig 1, c and d) (16.2 ±
2.5/ventral horn and 16.6 ± 3.1/ventral horn,
Table II. Summary of the lacZ gene expression in
sham control and ischemic spinal cords
Sham control 15-min ischemia
l d + + + – – –
2 d 3+ 3+ 3+ + + +
4 d 3+ 3+ 3+ 3+ 3+ 2+
7 d 3+ 3+ 3+ + + ±
Staining was categorized as follows: negative (–); partial/weak (±);
weak (+); moderate (2+); strong (3+). n = 3 at each time point.
Fig 2. Change in numbers of large motor neurons that were positive for lacZ in ventral gray
matter at 1, 2, 4, and 7 days after procedure.
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respectively) and the lacZ gene expression remained
in astrocytes in dorsal white matter.
In the ischemic spinal cord, none of the cells
expressed the lacZ gene at 1 day of reperfusion (0.0
± 0.0/ventral horn). At 2 days after reperfusion, the
lacZ gene was expressed in some astrocytes in dorsal
white matter and motor neurons in ventral horn
(Fig 1, f) (7.9 ± 3.5/ventral horn). The number
and staining gradually increased at 4 days of reper-
fusion with a peak on the same days (Fig 1, g) (11.1
± 3.0/ventral horn). At 7 days of reperfusion, the
gene expression returned to the level of 1 day and
some still weakly expressed lacZ gene in the motor
neurons (Fig 1, h) (2.7 ± 2.41/ventral horn).
Immunohistochemical study. Double staining
with lacZ and immunohistochemistry in sections
from spinal cords are shown in Figs 3 and 4. The
spinal cords of sham-operated animals did not show
Fas antigen immunoreactivity in motor neurons
expressing lacZ gene (Fig 3, a) (0.0% ± 0.0%, mean
± SD; Fas + lacZ positive motor neurons/Fas positive
motor neurons). Motor neurons positive for X-gal
showed a strong immunoreactivity for Fas antigen at
2 days of reperfusion after 15 minutes of ischemia
(Fig 3, b) (43.6% ± 9.8%). Immunoreactivity of
motor neuron cells for Fas antigen decreased at 4
days (38.9% ± 7.0%) and was lost in the motor neu-
rons at 7 days (17.4% ± 10.3%). Sections without first
antibody showed no staining (Fig 3, c).
DISCUSSION
We have previously demonstrated delayed and
selective motor neuron death in lumbar regions of
the rabbit spinal cord with the same reproducible
model.7,10,18 Fifteen minutes of ischemia is a rela-
tively short ischemic period in comparison with
those of previously reported models,13 and after the
ischemia, delayed and selective motor neuron dam-
age was observed only after 7 days of reperfusion in
this model.7,10,18 This phenomenon is known as
selective neuronal death in motor neuron cells after
spinal cord ischemia.7,10,18
Several methods have been proposed to protect
the pathophysiology of ischemic neuronal death,
including ischemic preconditioning, administration
of methylprednisolone, and cycloheximide.10,19,20
However, no method has been established that total-
ly prevents the development of neuronal cell death.
In recent years, the use of replication-defective ade-
noviral vectors has provided a novel strategy for
direct gene transfer into the brain.11-13 Initial exper-
imental models of gene transfer into the brain were
performed with replication-defective or latency-
prone neurotrophic viruses such as herpes simplex
virus type.21,22 Although herpes virus vectors can
carry a relatively large gene up to 36 kilobase,
cytopathogenicity such as neuronal death may be a
Fig 3. Immunostaining against Fas antigen in motor neu-
ron cells that express the lacZ gene in a sham spinal cord
(a) and 2 days (b) of reperfusion after 15-minute ischemia.
Black arrowheads show motor neuron cells that express
immunoreactive Fas antigen; white arrowheads show
motor neuron cells that express the lacZ gene. Sections
without first antibody showed no staining (c). (Bar = 50
m m in a, b; bar = 100 m m in c).
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major disadvantage.23,24 Retroviral vectors also have
a potential to deliver genes into the neurons.25,26
However, the retroviral vectors do not infect nondi-
viding cells such as neurons, and in vivo risks such as
mutagenesis and tumorigenesis are also indicat-
ed.23,24 Direct injection of plasmid vector with or
without conjugation of liposome also carries genes to
the brain.27 However, efficacy of gene expression is
low.23,24
The advantageous feature of adenoviral vectors is
that they are capable of infecting a variety of termi-
nally differentiated cell types such as neuron and mus-
cle.23,24 It was generally considered that ischemic
spinal cord usually has a translational problem of gene
expression and cannot effectively produce protein
even if the mRNA is present.6,8,9 Our present result
showed that motor neurons of ventral horn can effec-
tively express the lacZ gene as a functional protein in
ischemic spinal cord. This may be because the size of
the lacZ gene is relatively small (less than 500 base
pair) and the adenoviral vector locates in the episomal
position but is not incorporated in the genome like
retroviral vectors. This may also be due to a mild
reduction of protein synthesis in the case of ischemia,
and none or only a minimal protein expression may be
well correlated to the complete inhibition of protein
synthesis associated with calcium overload after reper-
fusion. In our previous study the lacZ gene expression
exploded with a recovery of protein synthesis at 7 days
of reperfusion in rat brain.28
Fas antigen is a cell surface protein that belongs to
the tumor necrosis factor and nerve growth factor
receptor family.29 Our previous study showed that the
increase of the immunoreactivity of apoptosis-induc-
ing protein, Fas antigen, was demonstrated in the
motor neuron cells in the spinal cord after transient
ischemia, and the peak of the immunostaining inten-
sity of Fas after ischemic insult preceded the DNA
fragmentation in the spinal cord.7 This finding sug-
gests that overexpression of Fas may play an impor-
tant role in induction of DNA fragmentation in the
spinal cord. The expression of Fas antigen precedes
the appearance of neuronal damage and may there-
fore be implicated in the activation of apoptosis.7
Fig 4. Change in percentage of large motor neurons that were positive for Fas and lacZ in
ventral gray matter at 1, 2, 4, and 7 days after ischemia.
The predominant localization of the staining in
the astroglia in dorsal white matter and anterior
motor neuron cells in ventral horn indicates that
viral particles rather than the enzyme were taken up
by axonal terminals and transported from dorsal
white matter to the ventral horn.ll A previous study
showed that adenoviral vector was injected into the
tumor of dorsal section of spinal cord; however,
motor neurons did not express lacZ gene.30 Our
study is the first report that the lacZ gene expresses
in ischemic motor neurons while the vector was
injected into dorsal white matter. A recent study
showed an attenuation of stroke size in rat brain
using intraventricular administration of adenoviral
vector expressing interleukin-1 receptor antagonist
in the periventricular ependymal cells.31 The present
study showed a potential of gene transfer and
expression in the motor neuron cells of ischemic
spinal cord.
In summary, we demonstrated transfer and
expression of lacZ gene in motor neuron cells that
were positive for Fas antigen, and Fas antigen
expression suggests the onset of apoptosis. The pres-
ent experimental results suggest a potential of gene
therapy for paraplegic patients after surgery with
possible future development of gene delivery and
injured tissue-specific target gene transfer.
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